Welcome to LookChem.com Sign In|Join Free
  • or
desacetylvinblastine hydrazide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

74741-42-7

Post Buying Request

74741-42-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

74741-42-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 74741-42-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,7,4 and 1 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 74741-42:
(7*7)+(6*4)+(5*7)+(4*4)+(3*1)+(2*4)+(1*2)=137
137 % 10 = 7
So 74741-42-7 is a valid CAS Registry Number.

74741-42-7Downstream Products

74741-42-7Relevant academic research and scientific papers

SYNTHESIS OF NAPAVIN, A NEW PHOTOREACTIVE DERIVATIVE OF VINBLASTINE

Nasioulas, Georgios,Grammbitter, Klaus,Gerzon, Koert,Ponstingl, Herwig

, p. 5881 - 5882 (1989)

The synthesis of 3-amino>carbonyl>-O4-deacetyl-3-de(methoxycarbonyl)-vincaleukoblastine (napavin) from vinblastine is described.This new photoreactive cytoststatic substance overcomes multidrug resistance

Method of treating cancer

-

, (2008/06/13)

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a glucocorticoid, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least one PSA conjugate and at least one glucocorticoid. The invention also relates to methods of preparing such compositions.

Method of treating cancer

-

, (2008/06/13)

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

Method of treating cancer

-

, (2008/06/13)

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a tachykinin receptor antagonist, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a tachykinin receptor antagonist. The invention also relates to methods of preparing such compositions.

CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER

-

Page 27, (2008/06/13)

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized

Method of treating cancer

-

, (2008/06/13)

The present invention relates to methods of treating cancer using a combination of a PSA conjugate and radiation therapy. The methods of this invention comprise administering to a mammal in need amounts of at least one PSA conjugate, in combination with radiation therapy, either sequentially or concomitantly.

Method of treating cancer

-

, (2008/06/13)

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and an NSAID compound, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and an NSAID compound. The invention also relates to methods of preparing such compositions.

Conjugates useful in the treatment of prostate cancer

-

, (2008/06/13)

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by a hydroxylalkylamino linker between the oligopeptide and vinblastine. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH). Also disclosed are novel cytotoxic agents that are derivatives of vinca alkaloid drugs.

Derivatives of 4-desacetyl VLB C-3 carboxyhydrazide

-

, (2008/06/13)

N2 derivatives of 4-desacetyl VLB (vinblastine) C-3 carboxyhydrazide, active anti-tumor agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 74741-42-7